https://www.selleckchem.com/pr....oducts/gsk2578215a.h
002), and antifungal therapy (7.3% vs 0, p = 0.042) were higher in the corticosteroids group than those in the non-corticosteroids group. Compared to the non-corticosteroids group, more patients developed severe disease (12.7% vs 1.8%, p = 0.028) in the corticosteroids group. There was nosignificantdifference between the two groups in mortality (1.8% vs 0, p = 0.315). In adult patients with non-severe COVID-19 pneumonia, early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes. In adult pat
Like
Comment
Share
